The stack
CJC-1295 Ipamorelin as a Growth Hormone Secretagogue
What a secretagogue actually is, how a GHRH-plus-GHRP combination amplifies the body's own GH pulse, and what the class data say about safety — read straight from the literature.
Before the details
A growth hormone secretagogue is anything that tells your body to make more of its own growth hormone (GH), rather than injecting GH from outside. CJC-1295 Ipamorelin is a growth hormone secretagogue combination: it nudges your pituitary gland to release more of your own GH through two separate switches at once. CJC-1295 mimics GHRH (one natural release signal); ipamorelin mimics ghrelin (a second release signal through a different receptor). The appeal of working this way is that it keeps GH coming out in natural-looking pulses with the body's own feedback brakes still in place, instead of flooding the system with outside hormone. That said, this is a research-chemical class with no FDA-approved members in this pairing, and raising GH carries real trade-offs. The rest of this page explains the class, the mechanism, and the honest safety picture.
What a growth hormone secretagogue is
A growth hormone secretagogue is a compound that stimulates the pituitary to secrete its own GH, as opposed to exogenous (externally supplied) GH. There are two broad families. GHRH analogues — like CJC-1295, sermorelin, and tesamorelin — copy the natural GHRH "release" signal and act through the GHRH receptor and the cAMP pathway. GHRPs (growth-hormone-releasing peptides) — like ipamorelin, GHRP-6, and GHRP-2 — act through the ghrelin receptor (GHS-R1a) and the calcium pathway. CJC-1295 Ipamorelin puts one of each family together: a GHRH analogue and a selective GHRP. The reason for using a secretagogue rather than GH itself is that the GH comes out in the body's own pulsatile rhythm, under intact negative feedback from IGF-1 [1].
How the combination amplifies the GH pulse
The two arms are complementary, not redundant. CJC-1295 raises cAMP through the GHRH receptor; ipamorelin raises intracellular calcium through the ghrelin receptor; the ghrelin arm additionally eases somatostatin (the body's GH brake). Because the pathways are independent, co-stimulation is supra-additive — it releases more GH than the sum of the parts. This was shown directly in humans, where a GHRP plus GHRH stimulated GH synergistically through independent mechanisms [3], and at the receptor level, where co-activating both receptors produced roughly twice the cAMP of GHRH alone [4]. The CJC-1295 half then sustains the GHRH signal for days thanks to its albumin-binding DAC [1][5], while ipamorelin contributes a clean, selective GH pulse [2].
Why selectivity matters in this class
Not all secretagogues are equally clean. Older GHRPs raised stress hormones alongside GH. Ipamorelin, the first selective GH secretagogue, did not raise ACTH or cortisol above GHRH-stimulated levels even at doses more than 200 times the amount needed for GH release, while matching GHRP-6's GH efficacy in swine [2]. That selectivity is the reason ipamorelin is the GHRP of choice for combining with a GHRH analogue: you get the synergistic GH boost without dragging the HPA (stress) axis along. It's the cleanest available expression of the GHRP half of a secretagogue stack.
What the class data say about safety
The best class-level synthesis: a review of GH secretagogues found them generally well tolerated, with the chief safety concern being increased blood glucose from decreased insulin sensitivity, and emphasized that long-term data on cancer incidence and mortality are still needed [6]. Because every secretagogue works by raising GH, the class shares GH's predictable trade-offs — mild glucose elevation, transient fluid retention, and the theoretical IGF-1-related proliferation concern that comes with chronically elevating a growth signal. None of this is specific to a trial of the CJC-1295 Ipamorelin combination, because no such trial exists; it's the honest class-level read. The full safety detail, cited and grounded in mechanism, is on CJC-1295 Ipamorelin effects.